Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRichard Chen, PA
Clinical InstructorAbout
Research
Publications
2026
Mutational patterns in a large cohort of parathyroid carcinomas
Pandya C, Uzilov A, Costa-Guda J, Bellizzi J, Taik P, Moe A, Strahl M, van der Tuin K, Stevenson M, Cavaco B, Cetani F, Marcocci C, Karhu A, Arola J, Schalin-Jäntti C, Morreau H, Thakker R, Schadt E, Sebra R, Li S, Chen R, Arnold A. Mutational patterns in a large cohort of parathyroid carcinomas. Journal Of Endocrinological Investigation 2026, 1-11. PMID: 41879893, DOI: 10.1007/s40618-026-02855-x.Peer-Reviewed Original ResearchMonitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Ravi N, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle S, Chen R, Uronis H. Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. Scientific Reports 2026, 16: 14766. PMID: 41872254, PMCID: PMC13168297, DOI: 10.1038/s41598-026-43178-4.Peer-Reviewed Original ResearchThe Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Hunter N, Parsons H, Cope L, Canzoniero J, Navarro F, El-Refai S, Anampa J, Sparano J, Rimawi M, Storniolo A, Mainor C, Nanda R, DeMichele A, Gupta G, Stringer-Reasor E, Lynce F, Cobain E, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang E, Blackwell K, Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow J, Chen R, Boyle S, Stearns V, Wolff A, Park B. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. Journal Of Clinical Oncology 2026, 44: 1283-1295. PMID: 41805422, DOI: 10.1200/jco-25-02934.Peer-Reviewed Original ResearchUltrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
Nishizaki D, Law A, Li B, Abbott C, Chen Y, Lee S, Pyke R, Keough K, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer. Npj Precision Oncology 2026, 10: 79. PMID: 41580469, PMCID: PMC12936199, DOI: 10.1038/s41698-026-01287-3.Peer-Reviewed Original Research
2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas A, Keough K, Galvao V, Alonso G, Olano A, Villar M, Oberoi A, Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro F, Li B, Pyke R, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen R, Boyle S, Toledo R. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clinical Cancer Research 2025, 32: 333-349. PMID: 41400436, PMCID: PMC12809116, DOI: 10.1158/1078-0432.ccr-25-2312.Peer-Reviewed Original ResearchLongitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Black J, Karasaki T, Abbott C, Li B, Veeriah S, Al Bakir M, Liu K, Huebner A, Martínez-Ruiz C, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Liu L, Grieco C, Grimes K, Navarro F, Pyke R, Bartha G, Keough K, Dea S, Ravi N, Lyle J, Harris J, Brown K, Blackhall F, Hassani F, Fennell D, McGranahan N, Shaw J, Abbosh C, Consortium T, Hackshaw A, Jamal-Hanjani M, Frankell A, Boyle S, Chen R, Swanton C. Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. Cell 2025, 188: 7083-7098.e18. PMID: 41205598, DOI: 10.1016/j.cell.2025.10.020.Peer-Reviewed Original ResearchClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, Howes T, Shotts K, Densmore J, Spasic M, Da Silva D, Chen R, Lata J, Skolnik J, Keler T, Yellin M, LaVallee T, Fairchild J, Boffo S, O’Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi S, Fong L. Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2025, 31: 1463-1475. PMID: 39964352, PMCID: PMC11995007, DOI: 10.1158/1078-0432.ccr-24-3693.Peer-Reviewed Original ResearchWhole genome sequencing-powered ctDNA sequencing for breast cancer detection
Garcia-Murillas I, Abbott C, Cutts R, Boyle S, Pugh J, Keough K, Li B, Pyke R, Navarro F, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Smith I, Turner N. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Annals Of Oncology 2025, 36: 673-681. PMID: 39914664, DOI: 10.1016/j.annonc.2025.01.021.Peer-Reviewed Original ResearchUltrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, Chen R, Harris J, Veeriah S, Colopi M, Bakir M, Liu W, Lyle J, Navarro F, Northcott J, Pyke R, Hill M, Thol K, Huebner A, Bailey C, Colliver E, Martínez-Ruiz C, Grigoriadis K, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Sivakumar M, Shaw J, Hackshaw A, McGranahan N, Jamal-Hanjani M, Frankell A, Chen R, Swanton C. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nature Medicine 2025, 31: 70-76. PMID: 39806071, PMCID: PMC11750713, DOI: 10.1038/s41591-024-03216-y.Peer-Reviewed Original Research
2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Tsimberidou A, Alayli F, Okrah K, Drakaki A, Khalil D, Kummar S, Khan S, Hodi F, Oh D, Cabanski C, Gautam S, Meier S, Amouzgar M, Pfeiffer S, Kageyama R, Yang E, Spasic M, Tetzlaff M, Foo W, Hollmann T, Li Y, Adamow M, Wong P, Moore J, Velichko S, Chen R, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey V, O’Donnell-Tormey J, Santulli-Marotto S, Butterfield L, Da Silva D, Fairchild J, LaVallee T, Padrón L, Sharma P. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Journal Of Experimental Medicine 2024, 221: e20240152. PMID: 39190534, PMCID: PMC11349049, DOI: 10.1084/jem.20240152.Peer-Reviewed Original Research